Company Overview - Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel oncology therapies for cancers with critical unmet medical needs [3] - The company targets promising biological pathways involved in cancer generation or progression, with a focus on hematological malignancies and prostate cancer [3] Key Products and Studies - ONCT-534 is an investigational dual-action androgen receptor inhibitor (DAARI) showing preclinical activity in prostate cancer models, particularly for patients with metastatic castration-resistant prostate cancer (mCRPC) who have resistance to current treatments [3] - Study ONCT-534-101 has completed enrollment and dosing in six cohorts for mCRPC treatment [3] - ONCT-808 is an investigational CAR T cell therapy targeting ROR1, demonstrating activity against multiple hematological malignancies and solid tumors [3] - Patients have been dosed under Study ONCT-808-101 with relapsed or refractory aggressive B-cell lymphoma, including those who failed previous CD19 CAR T treatment [3] - Zilovertamab, an investigational monoclonal antibody, has shown promising results in a Phase 1/2 study for patients with mantle cell lymphoma, chronic lymphocytic leukemia, and marginal zone lymphoma, achieving 100% progression-free survival at 42 months in a specific patient population [3] Upcoming Financial Results - Oncternal Therapeutics will report its second quarter 2024 financial results after U.S. market close on August 8, 2024, followed by a webcast for a business update [1][2]
Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial Results